Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term gantenerumab extension after WN29922/WN39658
CTR20212158Phase 3Terminated
- Sponsor
- Roche
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gantenerumab in Alzheimer's disease (AD), sponsored by Roche. Primary endpoint: Long-term safety and tolerability of subcutaneous gantenerumab. Started Sep 2021; status: terminated.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20212158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212158.